Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
33
ENSC Quote, Financials, Valuation and Earnings
Last price:
$1.59
Seasonality move
:
22.18%
Day range:
$1.55 - $1.65
52-week range:
$1.46 - $10.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.70x
P/B ratio:
4.71x
Volume:
68.9K
Avg. volume:
72.3K
1-year change:
-80.46%
Market cap:
$5.7M
Revenue:
$5.2M
EPS (TTM):
-$6.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENSC
Ensysce Biosciences, Inc.
|
$1.4M | -$0.93 | -61.42% | -61.21% | $19.23 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENSC
Ensysce Biosciences, Inc.
|
$1.60 | $19.23 | $5.7M | -- | $0.00 | 0% | 0.70x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.55 | $0.85 | $195.3M | 2.60x | $0.80 | 0% | 3.01x |
|
NNVC
NanoViricides, Inc.
|
$1.43 | $7.00 | $25.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.98 | $2.00 | $803K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENSC
Ensysce Biosciences, Inc.
|
23.23% | 1.817 | 5.05% | 0.73x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENSC
Ensysce Biosciences, Inc.
|
-- | -$3.7M | -299.93% | -330.2% | -758.69% | -$2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Ensysce Biosciences, Inc. vs. Competitors
-
Which has Higher Returns ENSC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -756.26% compared to Ensysce Biosciences, Inc.'s net margin of -255.85%. Ensysce Biosciences, Inc.'s return on equity of -330.2% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ENSCEnsysce Biosciences, Inc.-- -$1.29 $1.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ENSC or NBY?
Ensysce Biosciences, Inc. has a consensus price target of $19.23, signalling upside risk potential of 1101.56%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -45.16%. Given that Ensysce Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Ensysce Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENSCEnsysce Biosciences, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ENSC or NBY More Risky?
Ensysce Biosciences, Inc. has a beta of 1.149, which suggesting that the stock is 14.858% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ENSC or NBY?
Ensysce Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Ensysce Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENSC or NBY?
Ensysce Biosciences, Inc. quarterly revenues are $493.1K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Ensysce Biosciences, Inc.'s net income of -$3.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Ensysce Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences, Inc. is 0.70x versus 3.01x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENSCEnsysce Biosciences, Inc.0.70x -- $493.1K -$3.7M NBYNovaBay Pharmaceuticals, Inc.3.01x 2.60x $521K -$1.3M
-
Which has Higher Returns ENSC or NNVC?
NanoViricides, Inc. has a net margin of -756.26% compared to Ensysce Biosciences, Inc.'s net margin of --. Ensysce Biosciences, Inc.'s return on equity of -330.2% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ENSCEnsysce Biosciences, Inc.-- -$1.29 $1.2M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ENSC or NNVC?
Ensysce Biosciences, Inc. has a consensus price target of $19.23, signalling upside risk potential of 1101.56%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 389.51%. Given that Ensysce Biosciences, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Ensysce Biosciences, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENSCEnsysce Biosciences, Inc.0 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is ENSC or NNVC More Risky?
Ensysce Biosciences, Inc. has a beta of 1.149, which suggesting that the stock is 14.858% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ENSC or NNVC?
Ensysce Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENSC or NNVC?
Ensysce Biosciences, Inc. quarterly revenues are $493.1K, which are larger than NanoViricides, Inc. quarterly revenues of --. Ensysce Biosciences, Inc.'s net income of -$3.7M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Ensysce Biosciences, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences, Inc. is 0.70x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENSCEnsysce Biosciences, Inc.0.70x -- $493.1K -$3.7M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ENSC or OGEN?
Oragenics, Inc. has a net margin of -756.26% compared to Ensysce Biosciences, Inc.'s net margin of --. Ensysce Biosciences, Inc.'s return on equity of -330.2% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ENSCEnsysce Biosciences, Inc.-- -$1.29 $1.2M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ENSC or OGEN?
Ensysce Biosciences, Inc. has a consensus price target of $19.23, signalling upside risk potential of 1101.56%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 104.96%. Given that Ensysce Biosciences, Inc. has higher upside potential than Oragenics, Inc., analysts believe Ensysce Biosciences, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENSCEnsysce Biosciences, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is ENSC or OGEN More Risky?
Ensysce Biosciences, Inc. has a beta of 1.149, which suggesting that the stock is 14.858% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ENSC or OGEN?
Ensysce Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENSC or OGEN?
Ensysce Biosciences, Inc. quarterly revenues are $493.1K, which are larger than Oragenics, Inc. quarterly revenues of --. Ensysce Biosciences, Inc.'s net income of -$3.7M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Ensysce Biosciences, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences, Inc. is 0.70x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENSCEnsysce Biosciences, Inc.0.70x -- $493.1K -$3.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ENSC or PTN?
Palatin Technologies has a net margin of -756.26% compared to Ensysce Biosciences, Inc.'s net margin of --. Ensysce Biosciences, Inc.'s return on equity of -330.2% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENSCEnsysce Biosciences, Inc.-- -$1.29 $1.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ENSC or PTN?
Ensysce Biosciences, Inc. has a consensus price target of $19.23, signalling upside risk potential of 1101.56%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Ensysce Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Ensysce Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENSCEnsysce Biosciences, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is ENSC or PTN More Risky?
Ensysce Biosciences, Inc. has a beta of 1.149, which suggesting that the stock is 14.858% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ENSC or PTN?
Ensysce Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENSC or PTN?
Ensysce Biosciences, Inc. quarterly revenues are $493.1K, which are larger than Palatin Technologies quarterly revenues of --. Ensysce Biosciences, Inc.'s net income of -$3.7M is higher than Palatin Technologies's net income of --. Notably, Ensysce Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences, Inc. is 0.70x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENSCEnsysce Biosciences, Inc.0.70x -- $493.1K -$3.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ENSC or TOVX?
Theriva Biologics, Inc. has a net margin of -756.26% compared to Ensysce Biosciences, Inc.'s net margin of --. Ensysce Biosciences, Inc.'s return on equity of -330.2% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ENSCEnsysce Biosciences, Inc.-- -$1.29 $1.2M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ENSC or TOVX?
Ensysce Biosciences, Inc. has a consensus price target of $19.23, signalling upside risk potential of 1101.56%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3064.56%. Given that Theriva Biologics, Inc. has higher upside potential than Ensysce Biosciences, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Ensysce Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENSCEnsysce Biosciences, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ENSC or TOVX More Risky?
Ensysce Biosciences, Inc. has a beta of 1.149, which suggesting that the stock is 14.858% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ENSC or TOVX?
Ensysce Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENSC or TOVX?
Ensysce Biosciences, Inc. quarterly revenues are $493.1K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Ensysce Biosciences, Inc.'s net income of -$3.7M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Ensysce Biosciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences, Inc. is 0.70x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENSCEnsysce Biosciences, Inc.0.70x -- $493.1K -$3.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
